21st Annual University of Chicago Developmental Therapeutics Symposium
The goal of this activity is to help consortium members to assimilate requirements of new studies, review synthesized data from completed studies, discuss the novel investigational agents available from the National Cancer Institute and other sponsors, describe the rational for and results of studies that include new targeted agents for the treatment of patients with advanced and rare disease. This will enable participants, as applicable, to become stronger leaders in oncology research, provide new treatments for cancer patients and provide operations/administrative support for current and future oncology clinical trials, which will lead to improved outcomes for patients suffering from cancer.
This activity has been designed for physicians and other health care professionals currently involved in the diagnosis, screening, and treatment of cancer patients.
At the conclusion of this activity, participants will be able to:
- State the effects of the use of novel experimental agents from the National Cancer Institute and other sponsors;
- Cite the relevant pharmacology and biologic effects of novel anti-cancer agents through the use of blood and tissue samples as well as standard and novel imaging approaches;
- Recall upcoming cancer clinical trials/projects;
- Discuss advances in the use of chemotherapy and other targeted therapies for cancer;
- Describe the rational for and results of studies that include new targeted agents for the treatment of patients with advanced and rare disease.
- Use updated information to support clinical trial conduct as administrative systems evolve.
Walter Stadler, MD
Professor, Section Chief, Hematology/Oncology
Thomas Gajewski, MD
Professor of Medicine
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
REGISTRATION IS NOT OPEN TO THE PUBLIC